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Abstract
Dense genotype data can be used to detect chromosome fragments inherited from a common ancestor in apparently
unrelated individuals. A disease-causing mutation inherited from a common founder may thus be detected by searching for
a common haplotype signature in a sample population of patients. We present here FounderTracker, a computational
method for the genome-wide detection of founder mutations in cancer using dense tumor SNP profiles. Our method is
based on two assumptions. First, the wild-type allele frequently undergoes loss of heterozygosity (LOH) in the tumors of
germline mutation carriers. Second, the overlap between the ancestral chromosome fragments inherited from a common
founder will define a minimal haplotype conserved in each patient carrying the founder mutation. Our approach thus relies
on the detection of haplotypes with significant identity by descent (IBD) sharing within recurrent regions of LOH to
highlight genomic loci likely to harbor a founder mutation. We validated this approach by analyzing two real cancer data
sets in which we successfully identified founder mutations of well-characterized tumor suppressor genes. We then used
simulated data to evaluate the ability of our method to detect IBD tracts as a function of their size and frequency. We show
that FounderTracker can detect haplotypes of low prevalence with high power and specificity, significantly outperforming
existing methods. FounderTracker is thus a powerful tool for discovering unknown founder mutations that may explain part
of the ‘‘missing’’ heritability in cancer. This method is freely available and can be used online at the FounderTracker website.
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Introduction
With the advent of SNP arrays and next-generation sequencing,
it is now possible to genotype millions of SNPs in a single
experiment, at low cost. This has made it feasible to detect DNA
regions inherited from a common ancestor in two apparently
unrelated individuals. Two stretches of DNA are said identical by
descent if they are identical due to common ancestry. The
detection of identity by descent (IBD) in populations is considered
a highly promising approach to the linkage mapping of disease
genes. Indeed, linkage analyses are usually carried out in small
pedigrees containing closely related individuals. Consequently, the
IBD segments identified tend to be too long to delineate focal
regions of interest with a restricted number of candidate genes. By
contrast, tracts of IBD in unrelated individuals rarely span more
than a few centimorgans (cM). Population-based linkage studies
are thus very useful for the fine delineation of candidate loci [1].
Several powerful methods have been described for detecting tracts
of IBD between pairs of individuals, based on dense phased [2,3]
or unphased [4,5] genotyping data. These methods are useful for
pairwise IBD detection, but population-based linkage mapping
requires the detection of genomic regions with a significant excess
of IBD in cases of disease with respect to controls. Two methods
were recently proposed for the detection of IBD between multiple
individuals: a Markov Chain Monte Carlo approach (MCMC) [6],
and DASH (DASH Associates Shared Haplotypes) [7], a graph-
based algorithm which builds upon pairwise IBD segments to infer
clusters of IBD individuals. A major limitation of MCMC is that it
involves intense computation and is therefore not suitable for the
analysis of large data sets consisting of high-density SNP profiles.
DASH is much faster, but only returns a list of haplotypes that are
identical by descent in several samples. Significant enrichment in
disease cases may then be assessed through a statistical association
test. However, this approach only takes into account the frequency
of conserved haplotypes, and not their length. Yet, a long
haplotype, even encountered in a few cases, is likely to indicate
the presence of a founder mutation.
Our method is specifically dedicated to the mapping of cancer
genes. One key feature of cancers is that tumor cells accumulate
chromosome aberrations providing a growth advantage during
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becomes a highly rearranged version of the constitutive genome
of the patient. Besides, the location of somatic alterations is partly
driven by the presence of risk alleles in the germline genome [8].
In particular, patients inheriting a germline mutation in a tumor
suppressor gene frequently lose its normal counterpart in cancer
cells, revealing the mutant phenotype, as in Knudson’s two-hit
model [9]. Thus, germline mutations are often located in regions
of loss of heterozygosity (LOH). This feature is particularly useful
for the linkage mapping of cancer genes. Firstly, regions of LOH
can be used to prioritize the search for recurrent IBD. Secondly,
when a genomic region undergoes LOH, only one of the two
parental chromosomes remains in the tumor DNA, so the
haplotype of this chromosome is given directly by the tumor
SNP profile, without the need for a haplotype-phasing step.
Minimal regions of LOH are thus an ideal starting point for the
detection of recurrent IBD in a population sample of tumors.
Our method is designed for detecting cancer-associated
mutations inherited from a common founder, using recurrent
IBD in minimal regions of LOH (Figure 1). Building upon the
GERMLINE algorithm [3] for pairwise IBD detection in phased
haplotypes, we describe a scoring approach that takes into account
both the frequency and length of IBD segments for the
characterization of significantly conserved haplotypes in a set of
tumor samples. We validate this approach on two real cancer data
sets. In the first dataset, comprising 13 childhood adrenocortical
tumors from southern Brazil, we delineate a conserved haplotype
spanning 520 kb around the previously reported p.R337H TP53
founder mutation. In the second dataset, comprising 30 pheo-
chromocytomas and paragangliomas, we detect a novel founder
mutation of the SDHD gene, present in only two samples. Finally,
we show with simulated data that FounderTracker detects
conserved haplotypes of low prevalence with high power and
specificity, significantly outperforming existing methods.
Results
Detecting conserved haplotypes in recurrent regions of
LOH
Our strategy for the population-based linkage mapping of
founder mutations in cancer is illustrated in Figure 1. A mutation
spreading through a population is transmitted within a chromo-
some fragment from the common ancestor, which becomes
smaller from generation to generation due to genetic recombina-
tion at meiosis. All mutation carriers are thus identical by descent
to their common ancestor for the chromosome region harboring
the germline mutation. In addition, the wild-type counterpart of
the mutant gene is frequently lost by LOH in tumors occurring in
germline mutation carriers. Our approach to the mapping of
founder mutations using SNP array data thus involves (i)
identifying recurrent regions of LOH, (ii) reconstructing tumor
haplotypes in these regions, and (iii) searching for recurrent IBD in
tumor haplotypes.
With one probe targeting each of the two alleles of each SNP,
SNP arrays are an excellent tool for the genome-wide detection of
LOH, and several algorithms have been described for this purpose
[10,11]. In this study, we use the Genome Alteration Print method
[12] to detect LOH, defining a set of recurrent regions of LOH on
the basis of their frequency in the tumor data set.
We then reconstruct the haplotype of the retained allele in each
tumor (Figure 2). As only one of the two chromosomes remains in
the tumor due to LOH, the genotypes obtained for tumor DNA
directly provide the haplotype of the chromosome retained in
tumor cells. Incidentally, if constitutive DNA is also available, a
comparison of the unphased genotypes of constitutive DNA with
the tumor haplotype can be carried out to infer the haplotype of
the lost chromosome. To estimate the error rate associated with
this approach, we compared the haplotypes reconstructed for two
tumors from the same patient in which the same chromosome was
lost by LOH [13], and we obtained a very low error rate
(,5610
25).
Finally, we search for significantly recurrent IBD in the set of
reconstructed tumor haplotypes. The analytical pipeline for this
step is represented in Figure 3. Segments of pairwise IBD are first
identified with the GERMLINE algorithm [3]. We then assign a
score to each pairwise IBD segment, taking into account both the
number and the allelic frequencies of SNPs within each segment
(see Materials and Methods). An IBD score is then calculated for
each SNP marker, by summing the scores of all the pairwise IBD
segments containing this SNP. Linkage disequilibrium (LD) must
also be taken into account, because genomic regions of strong LD
will systematically have high IBD scores (Figure S1). We therefore
compare, for each SNP, the IBD score obtained for tumors with a
null distribution of IBD scores established using a reference set of
haplotypes from healthy controls (e.g. phased haplotypes from the
1,000 Genomes projects).
Application to the case of childhood adrenocortical
tumors in southern Brazil
As a proof-of-concept, we first applied our methodology to the
example of childhood adrenocortical tumors (ACT). These rare
cancers (0.3–0.4 cases per year per million children under the age
of 15 years) are exceptionally prevalent in southern Brazil (3.4–4.2
cases per million) [14], where they are almost invariably linked to
a specific germline mutation of TP53 (c.1010G.A, p.R337H)
[15,16], identified as a founder mutation [17]. We analyzed 13
Brazilian cases of ACT and six matched blood samples on
Illumina 370K SNP arrays. All tumors were found to carry the
p.R337H TP53 mutation. We used the Genome Alteration Print
method to detect LOH. This method identified two regions
displaying LOH in all samples: a 4.4 Mb region on 11p15, and the
entire chromosome 17. We then used FounderTracker to detect
significantly recurrent IBD in these two regions. No significant
region of IBD was detected in the 11p15 region (Figure S1), but
highly significant IBD scores were obtained for the 17p13 region
(q-value ,2.2610
–16). In particular, the peak IBD score defined a
520 kb region around the TP53 gene (Figure 4a). Detailed
haplotype analysis revealed that the mutated copies retained in
the 13 tumors displayed an identical haplotype for this region,
whereas the wild-type copies reconstructed for the six patients with
matched blood samples displayed different haplotypes (Figure 4b).
This recurrent IBD segment thus corresponds to the chromosome
fragment carrying the p.R337H TP53 mutation inherited by all
the patients from the common founder, which has not been
disrupted by crossover in the lineage.
The mean length of pairwise IBD tracts around TP53 was
5.4 cM (ranging from 0.88 cM to 19 cM, Figure S2). As pairwise
IBD segments are estimated to have a length of 1/(2n) Morgans
after n generations (hence 2n meiosis) [2], this suggests that the
p.R337H TP53 mutation occurred around nine generations ago.
Application to the case of pheochromocytomas and
paragangliomas
Pheochromocytomas and paragangliomas are neuroendocrine
tumors arising from the adrenal medulla and from sympathetic or
parasympathetic paraganglia tissues respectively. These tumors
occur in the context of inherited cancer syndromes in ,30% of
IBD Mapping of Founder Mutations in Tumor SNP Data
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mocytoma include mutations of RET, NF1, VHL, TMEM127,
MAX, and genes encoding proteins from the succinate dehydro-
genase complex (SDHA, SDHB, SDHC, SDHD and SDHAF2).
Here, we applied our methodology for founder mutation discovery
to a set of 30 pheochromocytomas/paragangliomas from unrelat-
Figure 1. IBD mapping of founder mutations in recurrent regions of LOH. This diagram illustrates the principles underlying our method. A
founder mutation (red star on the schematic diagram of chromosomes) spreads through a population within a chromosome fragment (in red)
inherited from the ancestral founder (A). Due to crossing-overs (dashed lines) between homologous chromosomes at meiosis, this chromosome
fragment is shortened over generations, such that mutation carriers (indicated in red) eventually harbor only a short identical by descent (IBD)
haplotype around the mutant gene (B). In addition, the wild-type counterpart of germline mutations is frequently lost by LOH in tumors, such that
the founder mutation typically lies within a minimal region of LOH (C). As a result, the founder mutation is located within a haplotype conserved in
each mutation carrier (peak IBD score), in the minimal region of LOH (D).
doi:10.1371/journal.pone.0035897.g001
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mutations, and analyzed on Illumina 610K SNP arrays. LOH
analysis revealed ten regions with LOH frequency above 20%, at
1p, 3p, 3q, 6q, 11p, 11q, 17p, 17q, 21q, and 22q (Figure 5A, top).
For these regions, tumor haplotypes were reconstructed from the B
Allele Frequency profiles, and analyzed with FounderTracker to
detect conserved chromosome segments. This analysis revealed a
2.34 cM region with significant IBD at 11q23.1 (Figure 5A,
bottom). Interestingly, this chromosome segment contains 32
genes including SDHD, and is identical by descent in two samples
(HS_048 and HS_158, Figure 5B), which are precisely the two
samples in our cohort for which a c.64C.T (p.Arg22X) germline
SDHD mutation was identified (Table S1). This finding demon-
strates that the p.Arg22X SDHD mutations in these two seemingly
unrelated patients originate from a single founder, and further
validate the relevance of our method for detecting founder
mutations in cancer.
Evaluation of the power of the method with simulated
data
Childhood ACT is an ideal case study for population-based
linkage mapping. As this disease is extremely rare in absence of the
p.R337H TP53 founder mutation, all of the samples selected
through a random sampling of tumors bear this mutation. In most
contexts, tumors attributable to a given founder mutation account
for only a subset of cancers in a population. We have shown with
the pheochromocytoma/paraganglioma data set that Founder-
Tracker was able to detect a founder mutation present in only 2
out of 30 samples (7%). To further evaluate the performance of
our method, we generated simulated data into which we artificially
introduced conserved haplotypes of different lengths and frequen-
cies. We benchmarked FounderTracker by analyzing the same
simulated data with the DASH algorithm, recently developed to
detect clusters of individuals sharing an identical haplotype [7],
which we adapted to our purposes (see Material and Methods).
Figure 2. Haplotype inference from tumor SNP profiles. Genotypes can be inferred from SNP array data, with the B allele frequency (BAF),
which characterizes the fluorescence ratio between the A and B alleles at each locus: BAF=B/(A+B). In constitutive DNA, each SNP is present as two
alleles. The genotype of each SNP (AA, AB, or BB) can thus be determined from the BAF (0, 0.5 or 1, respectively), but not the haplotype of each
chromosome. By contrast, if one of the two copies has been lost by LOH in the tumor, the tumor SNP profile directly reflects the haplotype of the
chromosome that is retained in the tumor. If paired constitutive and tumor DNA samples are available, the haplotype of the lost chromosome can be
reconstructed by comparing the two profiles.
doi:10.1371/journal.pone.0035897.g002
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(Figure S3), validating its relevance as a benchmark method.
All haplotypes conserved in $50% samples were successfully
detected by either method (Table 1). Both FounderTracker and
DASH were able to detect haplotypes conserved in $15% samples
with good power (.0.9), but FounderTracker significantly
outperformed DASH in the low frequency range (#10%)
(Table 1, Figure 6). The ROC curves indicate that Founder-
Tracker detects recurrent IBD segments with high sensitivity and
specificity down to a minimum frequency that depends on the
length of IBD segments. IBD tracts of 5 cM are detected with
good power (.0.9) from a frequency of 5%, whereas short
segments of 1 cM are detected with the same power only at
frequencies $15%. The false discovery rate, calculated across all
simulations, was negligible for both methods (respectively
8.6610
23 and 5.4610
24 for FounderTracker, and DASH).
The simulated data presented here correspond to the SNP
content of the Illumina 1M-Duov3 beadchip (1,199,187 markers).
To assess the impact of SNP density on the performance of the
method, we analyzed the same simulated data, restricted to the
sole 373,397 SNPs of the Illumina HumanCNV370-Quad chip.
Although there was a slight degradation in the detection of short
haplotypes (0.5 cM) with Illumina CNV370 array, we obtained a
comparable level of performance with both marker densities
(Figure S4). It has been estimated that 85% of the human genome
is spanned by haplotype blocks of 10 kb or larger in European
samples [19] so that the majority of common SNPs are well
captured by whole-genome genotyping arrays containing 100,000
markers or more, either directly or through linkage disequilibrium
[20]. Our results are consistent with this figure and provide
important information about the range of applicability of our
method, suggesting that the power achievable with the current
generation of arrays is close to the maximal power of IBD
mapping.
The running time of FounderTracker is linearly associated with
the number of samples and SNP markers analyzed. For example,
the processing of the childhood ACT dataset (13 samples, 9,762
SNPs) took 4 min 07 seconds, and the longest run in our
simulations, for a dataset of 100 chromosome 1 haplotypes
(80,158 SNPs), took 2 hours 48 minutes on a single core of an
Intel Xeon X5470 Quad-Core processor running at 3.33 GHz.
However, as noted above, little increase in power would be
expected from the analysis of denser SNP data, so the amount of
data analyzed can be constrained, in terms of markers, to the
current SNP content of high-definition arrays.
Discussion
Most of the founder effects detected to date were revealed by
targeted studies of polymorphic markers around well known
cancer-related mutations. We introduce here the first systematic
approach for detecting founder mutations on a genome-wide basis,
from dense SNP profiles of tumor samples.
SNP arrays are widely used in cancer research for two main
purposes: the discovery of germline risk variants in linkage or
association studies, and the identification of recurrent chromo-
some rearrangements. Researchers typically study exclusively the
germline genome for association studies, or the tumor genome for
the analysis of chromosome rearrangements, but a combined
analysis of risk alleles and chromosome aberrations has been
shown to be fruitful [21]. In this study, we used LOH to prioritize
regions of interest for IBD mapping. One of the limitations of this
approach is that other mechanisms, such as mutation or promoter
hypermethylation, may inactivate the wild-type counterpart of a
mutant gene in the absence of LOH. However, previous studies
have shown LOH to be a common ‘‘second hit’’ in germline
mutation carriers [22,23]. Our approach is thus likely to be
relevant in a large proportion of cases. In addition, high-
Figure 3. Detecting significantly recurrent IBD in a set of tumor haplotypes. The FounderTracker pipeline for recurrent IBD detection is
divided into two steps. An IBD score is first calculated for each SNP marker in the tumor set of haplotypes. The IBD score is derived from the pairwise
IBD segments identified with the GERMLINE algorithm. It takes into account their length and the allelic frequencies of SNPs within each segment. The
IBD score for tumors is then compared with a null distribution established from a reference data set, to identify the SNPs with IBD scores significantly
higher than expected by chance.
doi:10.1371/journal.pone.0035897.g003
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regions of LOH. IBD detection can thus be carried out with
stringent parameters, making the method highly specific. Finally,
LOH at a cancer gene locus is likely to be more frequent in
mutation carriers than in non-carriers, as already shown for the
BRCA genes [24]. By considering only samples with a LOH for
each candidate region, we may thus be able to detect conserved
low-frequency haplotypes that would not have been detected as
significant by considering the whole tumor set.
No existing approach was exactly designed for the systematic
detection of founder mutations in cancer, but the DASH method
for detecting clusters of haplotypes sharing identity-by-descent
could be easily adapted to our purposes. The difference between
FounderTracker and DASH lies in the characterization of
significantly recurrent IBD from pairwise IBD matches. DASH
identifies clusters of haplotypes conserved in several samples. One
can then test whether one of these haplotypes is significantly
overrepresented in tumors, as compared to normal controls. A
limitation of this approach is that, once clusters are identified, the
association test does not take into account the length of conserved
haplotypes. By contrast, the FounderTracker approach evaluates
an IBD score that takes into account both the frequency and the
length of conserved haplotypes. As a result, FounderTracker
significantly outperformed DASH for detecting haplotypes con-
served in #10% samples. This makes an important difference in
terms of applications, since founder mutations are likely to be
relatively rare in most cases. For instance, a founder mutation
present in only 5% of tumors, lying within a conserved haplotype
of mean length 5 cM, (like the p.R337H TP53 mutation in
Brazilian ACT) will be detected with a power of 0.92 with
FounderTracker versus 0 with DASH (Table 1). Besides, the
haplotype around SDHD, conserved in two paragangliomas, is not
detected by DASH (Figure S5). Another existing method for
detecting IBD in multiple individuals is the Markov Chain Monte
Carlo (MCMC) approach [6]. However, this method is highly
computation-intensive and the authors described its application to
small data sets only (maximum of 15 samples and 1278 SNPs).
When we tried to apply this approach to our set of data for
childhood adrenocortical tumors, the method failed to converge
after several days. By contrast, FounderTracker was able to
process the same dataset in a few minutes. We conclude that
MCMC is not very suitable for the analysis of high-definition SNP
array data.
Figure 4. A conserved haplotype around the TP53 founder mutation in childhood adrenocortical tumors. The IBD score calculated
along chromosome 17 for the set of 13 childhood adrenocortical tumors (ACT) displays a significant peak at 17p13.1 (A). The sharp increases in the
IBD score curve correspond to the boundaries of IBD segments in each pair of tumors. The peak region is represented in detail in panel B, with the
haplotypes of the 13 chromosome copies retained in the tumors (harboring the mutant TP53 allele), and the haplotypes of the chromosome copies
lost by LOH (harboring a wild-type TP53 allele) reconstructed for the six patients with matched normal blood samples. The haplotypes of wild-type
alleles are all different, demonstrating the existence of different haplotypes for this genomic region in the population analyzed. By contrast, a
haplotype common to all mutant alleles spans 470 kb upstream and 32 kb downstream from TP53 (represented by a thick red line). This conserved
haplotype corresponds to the chromosome fragment harboring the R337H TP53 mutation inherited from the ancestral founder.
doi:10.1371/journal.pone.0035897.g004
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conserved haplotypes of at least 0.5 cM in length (Figure S4).
Chapman et al. showed that, after 100 generations of random
mating in a growing population, IBD tracts would have a mean
length of 0.6 cM [25]. Our method is therefore suitable for the
detection of cancer-related mutations that appeared less than 100
generations ago. Since FounderTracker relies on the null
distribution of IBD scores to identify significantly conserved
haplotypes, we strongly encourage FounderTracker users to use
reference samples of the same ancestry as the tumor samples to
calculate null distributions. In absence of a Brazilian reference
data set, we used the CEU data of the 1,000 Genomes project as a
reference for the analysis of adrenocortical tumors, because the
population of the Parana state is predominantly of European
origin [26].
In terms of frequency, FounderTracker can detect, with high
power, haplotypes conserved in more than 5% of samples,
depending on the length of the IBD segments. The proportion
of tumors harboring a founder mutation in a random population
sample depends principally on the genetic diversity of the
Figure 5. Detection of a long conserved haplotype around SDHD gene in two paragangliomas. (A) LOH analysis revealed 10 chromosome
arms with LOH frequency .20% in our set of 30 pheochromocytomas and paragangliomas (top). These regions were analyzed using FounderTracker
to detect conserved haplotypes, revealing a single significant region on chromosome arm 11q (bottom). (B) Visualization of the significant region
identified on chromosome 11 with the Integrative Genomics Viewer [44]. The IBD score is represented as a blue line above tumor haplotypes.
Haplotypes are represented as series of blue and yellow vertical lines, corresponding to SNPs with respectively ‘‘A’’ and ‘‘B’’ genotype, according to
Illumina nomenclature. The significant region detected by FounderTracker corresponds to the long haplotype that is identical in tumors HS_048 and
HS_158, and results in a high IBD score for this segment. This region contains 32 genes, including SDHD (indicated in red).
doi:10.1371/journal.pone.0035897.g005
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as childhood ACT, with a higher prevalence in a specific
geographic area are ideal for IBD mapping, because almost all
cases are due to the founder mutation. In common diseases, such
as breast cancer, high-frequency founder mutations were initially
described in geographically or culturally isolated populations. For
example, the BRCA1 and BRCA2 founder mutations were initially
discovered in the Ashkenazi Jewish population [27,28] and in
Finland [29], respectively. However, the extensive analysis of these
two genes in numerous geographic areas has since revealed the
existence of more than 20 different founder mutations in different
regions [30]. These findings suggest that founder mutations may
be more common than currently thought. FounderTracker can be
used online through a web application, and the source code can be
downloaded from our web page (http://cit2.ligue-cancer.net/
FounderTracker).
Materials and Methods
Patients and ethics statement
Thirteen ACT patients from a Brazilian cohort [31] were
included in this study. Ethical approval for the study was obtained
from the Pequeno Prı ´ncipe Hospital Ethics Committee (Curitiba,
Brazil) and CONEP (Federal Ethics Committee in Brasilia, Brazil)
in 2009. In all cases, one of the parents or legal representatives
signed an informed consent form approved by the local ethics
committee. DNA was extracted from the tumor and peripheral
blood as previously described [31]. TP53 mutation analysis was
performed as previously described [32].
Table 1. Power to detect conserved haplotypes as a function of haplotype length and prevalence.
Size Method 2% 3% 5% 7% 10% 15% 20% 50%
1c M FounderTracker 0.02 0.02 0.11 0.29 0.65 0.94 0.9 1
DASH 0 0 0 0.03 0.36 0.9 0.95 1
2c M FounderTracker 0.01 0.04 0.35 0.83 0.98 0.99 1 1
DASH 0 0 0 0.13 0.8 1 1 1
5c M FounderTracker 0.06 0.27 0.92 1 1 1 1 1
D A S H 0000 . 4 7 1111
doi:10.1371/journal.pone.0035897.t001
Figure 6. Power analysis with simulated data. The performance of FounderTracker was assessed under various conditions, by comparison with
the DASH method. The ability of each method to detect conserved haplotypes was established as a function of haplotype length (1 to 5 cM) and
prevalence (2 to 10% of the samples). For each condition, the mean ROC curve was established by applying each method to 100 simulated datasets.
doi:10.1371/journal.pone.0035897.g006
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paraganglioma from the French COMETE network, collected by
the Georges Pompidou European Hospital, were included in this
study. Ethical approval for the study was obtained from the
institutional review board (CPP Paris-Cochin, January 2007). All
patients provided written informed consent for the collection of
samples and subsequent analyses. Tumor DNA was extracted as
previously described [33]. Clinical NF1 diagnosis and genetic
testing for RET, SDHA, SDHB, SDHC, SDHD and VHL was
performed as previously described [33].
SNP array hybridization and preprocessing
The 13 adrenocortical tumor samples were analyzed with
Illumina HumanCNV370-Duo v1.0 chips, containing 370,404
probes, and the six matched normal samples were analyzed with
Illumina HumanCNV370-Quad v3.0 chips, containing 373,397
probes. The 30 pheochromocytomas/paragangliomas were ana-
lyzed with Illumina Human610-Quad v1.0 chips, containing
620,901 probes. Hybridization was performed by IntegraGen
(Evry, France), according to the instructions provided by the array
manufacturer. Raw fluorescent signals were imported into
Illumina BeadStudio software and normalized, as previously
described [34], to obtain the log R ratio (LRR) and B allele
frequency (BAF) for each SNP. The tQN normalization procedure
was then applied to correct for the asymmetry in BAF signals due
to the bias between the two dyes used in Illumina assays [35].
Detection of LOH
Genome-wide copy-number changes in tumors were deter-
mined as previously described [12]. The genomic profiles were
divided into segments by applying the circular binary segmenta-
tion algorithm (DNAcopy package, Bioconductor) [36,37] to the
LRR and BAF signals separately. The allele-specific copy number
of each segment was then determined by the Genome Alteration
Print (GAP) method [12]. In brief, the GAP pattern of each sample
(a sideview projection of segmented LRR and BAF) was
constructed, and the best-fitting GAP model was used to
determine the ploidy of the sample, the level of contamination
with normal cells and the absolute copy number and genotype
corresponding to each cluster of segments. We considered a
segment to have undergone LOH when the copy number of the
minor copy of the segment was ,0.5. Note that throughout this
paper, LOH refers to any chromosome region in which one of the
parental copies has been completely lost, whatever the copy
number of the retained chromosome.
Inferring tumor haplotypes from B allele frequency
profiles
In a genomic region of LOH, the BAF profile is either close to 0
(A allele retained) or close to 1 (B allele retained). We used fixed
thresholds to reconstruct tumor haplotypes in regions of LOH.
SNPs with a BAF.0.65 were assigned the genotype B, whereas
SNPs with a BAF,0.35 were assigned the genotype A. We
considered SNPs with a BAF between these two thresholds in at
least one of the tumors to be unreliable, and removed them from
the analysis. We estimated the error rate for haplotype inference
by this method, by analyzing previously published data for two
tumors from a single patient that displayed LOH for the same
chromosomes [13] and comparing the haplotypes reconstructed
independently for each sample.
Detection of significantly recurrent IBD in tumor
haplotypes
Once recurrent regions of LOH have been established and
tumor haplotypes within these regions have been reconstructed,
the FounderTracker pipeline is used to detect haplotypes that are
significantly conserved in each candidate region. FounderTracker
first assigns an IBD score to each SNP in the region. The
significance of each IBD score is then assessed by comparison with
a null distribution obtained from a reference set of haplotypes.
Detecting pairwise IBD with GERMLINE. The first step
in our scoring approach is the identification of pairwise IBD in the
set of tumor haplotypes. The GERMLINE algorithm has been
shown to be a robust tool for detecting pairwise IBD from phased
haplotype data [3]. In this study, we used GERMLINE version
1.5, downloaded from the GERMLINE web page (http://www1.
cs.columbia.edu/ ˜gusev/germline/), with default settings, except
that: (i) the minimum length for a match (-min_m) was set to
0.4 cM, to allow the detection of short IBD segments, (ii) the
number of mismatching markers allowed (-err_hom) was set to 0,
because the error rate for the inference of haplotypes from tumor
samples was shown to be negligible, (iii) the size of each slice used
for exact matching seeds (-bits) was set to 5, to increase the
accuracy of IBD boundaries.
Calculating the IBD score. The GERMLINE algorithm
provides output in the form of a list of pairwise IBD segments with,
for each segment, the indices of the first and last probe delineating
the segment, and the identifiers of the two samples sharing
identical haplotypes. We added a score to each segment to
characterize the significance of pairwise IBD. As a series of
common alleles is more likely to be identical in two samples by
chance, our score takes into account both the length of the
segment and the allelic frequencies of the probes defining the
common haplotype. Let us denote by H a haplotype of N SNPs
identical in two samples of the dataset. H is a vector H[ A,B ðÞ
N
such that Hi represents the allele of the i
th SNP (A or B) in the
conserved haplotype. The score S associated with the pairwise IBD
segment of haplotype H is given by the formula below, where Bfreqi
is the allelic frequency of the B allele for the i
th SNP:
SH~{log10 P
i=Hi~A
1{Bfreqi ðÞ
2| P
i=Hi~B
Bfreq2
i
  
This score corresponds to the log-transformed probability of
observing these two identical haplotypes by chance if all SNPs
were independent.
An IBD score is then calculated for each SNP i, by summing the
scores of all the pairwise IBD segments containing that SNP:
IBDscorei~
P
i[H
SH
Estimating the null distribution of IBD scores. The IBD
score described above characterizes the recurrence of IBD at a
given SNP location. It takes into account the length of IBD
segments and the allelic frequencies of SNPs, but not the linkage
disequilibrium between SNPs. This bias is corrected by comparing
the IBD score of each SNP with the distribution of IBD scores for
the same SNP under the null hypothesis that no haplotype shows
significant IBD in the set of samples. This distribution is
established by generating 100 reference haplotype subsets, of the
same size as the tumor set, by random sampling in a reference data
set of phased haplotypes (e.g. from the HapMap [38,39] or 1,000
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SNP in each of these subsets. The null distribution is then
approximated to the Gumbel distribution that best fits the
distribution of scores obtained in the 100 reference haplotype
subsets. The Gumbel distribution was preferred here to the
Gaussian distribution because it yielded a better approximation of
the empirical null distributions and more conservative estimates of
the p-values. For both the analysis of childhood adrenocortical
tumors and pheochromocytomas, we used as reference the 174
phased CEU haplotypes of the 1,000 Genomes project, down-
loaded together with the recombination rate file from the
IMPUTE web page:
https://mathgen.stats.ox.ac.uk/impute/impute_v2.
html#download_reference_data.
Assessing the significance of IBD scores. In the final step
of the pipeline, FounderTracker assigns a p-value to each SNP by
comparing the IBD score observed in the tumor set of haplotypes
to the null distribution established as described above. This p-
value represents the probability of obtaining a higher IBD score by
chance than the IBD score obtained for the set of tumor
haplotypes. Q-values are calculated from the p-values by the
Benjamini-Hochberg method [41], to control for false discovery
rate.
Dash
The DASH (DASH Associates Shared Haplotypes) algorithm
[7] builds upon pairwise IBD shared segments to infer clusters of
IBD individuals. To detect haplotypes significantly conserved in
tumors, we first apply GERMLINE to a combined set comprising
the tumor haplotypes together with a set of reference haplotypes
(here the CEU haplotypes from the 1,000 Genomes project). We
then use DASH to detect clusters of IBD from the pairwise IBD
matches identified by GERMLINE. Finally, we test through a
Fisher’s exact test whether each IBD cluster is significantly more
frequent in tumors than in reference haplotypes.
Assessing the performance of the methods with
simulated data
The performance of each method was evaluated by analyzing
simulated datasets with IBD segments of different sizes (1, 2 or
5 cM) conserved in various proportions of the samples (2 to 50%).
We included, in the simulated data, all the SNPs present on the
Illumina 1M-Duov3 beadchip, to model the performance that
could be expected with the use of a commercial array containing
,10
6 SNPs. For these simulations, we used a set of 548 phased
haplotypes from the 1,000 Genomes project, comprising data from
the CEU, GBR and TSI panels. This set was split in two sets of
274 haplotypes each, one of which (EUR1) was used as reference
data set, and the other (EUR2) was used to generate simulated
tumor data sets.
For each simulation, a chromosome was chosen at random, and
100 haplotypes of this chromosome were picked up in the EUR2
haplotype set, to constitute a simulated data set of 100 tumors. A
genomic location was then randomly selected on the chromosome,
and the haplotype of the first sample for this region was repeated
in the desired proportion of samples. In a real data set of tumors
harboring a founder mutation, all patients have inherited a
different chromosome segment from the founder. These segments
all comprise the mutation, but they have different boundaries. To
reproduce this variability, the size of the conserved haplotype in
each sample was randomly picked up from a Gumbel distribution
of location and scale equal to the desired mean haplotype length.
Such distribution was found to reproduce well the natural
variation in IBD lengths observed around the TP53 founder
mutation in adrenocortical tumors.
FounderTracker and DASH were then applied to the same
simulated data, and the rates of true positives (significant SNPs
within the conserved haplotype) and false positives (significant
SNPs outside the conserved haplotype) were determined at a series
of q-value thresholds, with the PresenceAbsence R package [42],
to reconstruct the ROC curve associated with each method. For
each size and proportion, 100 simulations were carried out and the
mean ROC curve was calculated. Power and false discovery rates
were calculated using the threshold q=0.01 for both methods.
Availability
FounderTracker can be used online through a web application,
and the source code can be downloaded from our web page
(http://cit2.ligue-cancer.net/FounderTracker). The SNP data
from the two tumor datasets analyzed in this study have been
deposited in NCBI’s Gene Expression Omnibus [43] and are
accessible through GEO Series accession number [GEO:
GSE32206].
Supporting Information
Figure S1 IBD score and significance across the 11p15
region in childhood adrenocortical tumors. The IBD score
in tumors (top) displays some peaks, but these peaks correspond to
normal variations due to the pattern of linkage disequilibrium
across the region and are also encountered in the null distribution
of IBD scores (middle). Thus, no significant IBD is detected in this
region (bottom).
(PDF)
Figure S2 Length of IBD segments between the different
pairs of childhood adrenocortical tumors. This image,
exported from the Integrative Genomics Viewer [44], displays the
IBD score along the 17p arm (top) and the tumor haplotypes
ordered according to the extent of their pairwise IBD with other
samples (bottom). The longest pairwise IBD segment, between
samples HS_07 and HS10 (green rectangle), spans 8 Mb. By
contrast, the smallest pairwise IBD segment, between samples
HS_01 and HS_14, spans only 520 kb, defining the minimal
haplotype conserved in all samples, corresponding to the peak IBD
score.
(PDF)
Figure S3 Application of FounderTracker (top) and
DASH (bottom) to the analysis of chromosome 17 in
the childhood adrenocortical tumor dataset. Both methods
detect the conserved haplotype around the TP53 gene.
(PDF)
Figure S4 Power analyses of simulated data for the SNP
content of Illumina 370K (in blue) or 1M (in red) SNP
arrays.
(PDF)
Figure S5 Application of FounderTracker (top) and
DASH (bottom) to the detection of significantly recur-
rent IBD on the 11q arm of 11 pheochomocytomas and
paragangliomas.
(PDF)
Table S1 Clinical data for the 30 pheochromocytoma and
paraganglioma samples.
(XLS)
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